Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib

BACKGROUND: Poly (ADP-ribose) Polymerase (PARP) inhibitors are promising novel radiosensitisers. Pre-clinical models have demonstrated potent and tumour-specific radiosensitisation by PARP inhibitors. Olaparib is a PARP inhibitor with a favourable safety profile in comparison to clinically used radi...

Descripción completa

Detalles Bibliográficos
Autores principales: de Haan, R., van Werkhoven, E., van den Heuvel, M.M., Peulen, H. M. U., Sonke, G. S., Elkhuizen, P., van den Brekel, M. W. M., Tesselaar, M. E. T., Vens, C., Schellens, J. H. M., van Triest, B., Verheij, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734274/
https://www.ncbi.nlm.nih.gov/pubmed/31500595
http://dx.doi.org/10.1186/s12885-019-6121-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734274/
https://www.ncbi.nlm.nih.gov/pubmed/31500595
http://dx.doi.org/10.1186/s12885-019-6121-3

Ejemplares similares